Damian Herrera
Arcutis Biotherapeutics (NASDAQ: ARQT) director Sue-Jean Lin sold 4,946 shares of common stock on June 15, 2026, for approximately $121,000, according to an SEC Form 4 filing. The transaction, executed at $24.38 per share, trimmed her direct holdings by roughly 15% — leaving her with 27,567 shares valued near $705,000.
At a Glance
- Lin sold 4,946 shares at $24.38 each on June 15, 2026
- Post-sale direct stake: 27,567 shares (~$705,000)
- Sale conducted under a prearranged trading plan
- ARQT shares are up nearly 90% over the past year
- Arcutis carries a market cap of $3.28 billion with $415.62 million in trailing-twelve-month revenue
A Prearranged Sale, Not a Red Flag
The transaction was carried out under a prearranged trading plan, the kind insiders use to sell shares on a set schedule regardless of market conditions. That context matters. Lin reduced her position, yes, but she still holds a meaningful chunk of the company — more than 27,500 shares — so her financial interest in Arcutis' trajectory isn't going anywhere.
Insider sales tend to draw outsized attention, but a director offloading around 15% of a position via a scheduled plan is a far cry from a distress signal. The more telling story here is what's happening with the business itself.
ZORYVE's Momentum Carries the Quarter
Arcutis built its commercial identity around its ZORYVE franchise, a line of topical therapies targeting chronic skin conditions including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. First-quarter net product revenue from ZORYVE climbed 65% year over year to $105.4 million, driven by steady prescription growth across all three approved indications.
That growth held up even against a traditional Q1 headwind: insurance deductible resets, which typically suppress prescription fills early in the year. Despite that drag, ZORYVE held its position as the leading prescribed branded topical treatment across its approved categories, according to management commentary.
CEO Frank Watanabe pointed to strong demand continuing into the period and flagged two pipeline developments worth watching — a supplemental FDA filing that could extend ZORYVE's use to infants as young as three months, and the launch of a first-in-human study for the company's investigational compound ARQ-234.
Narrowing Losses, Positive Cash Flow
Arcutis posted a quarterly net loss of $11.3 million, down sharply from $25.1 million in the same period a year earlier. The company also generated positive operating cash flow during the quarter — a meaningful milestone for a commercial-stage biotech still investing heavily in its pipeline.
Full-year revenue guidance remains at $480 million to $495 million. Whether Arcutis can keep converting prescription volume into sustainable profitability is the real question hanging over the stock.
| Metric | Value |
|---|---|
| Shares sold | 4,946 |
| Sale price per share | $24.38 |
| Transaction value | ~$121,000 |
| Post-sale shares held | 27,567 |
| Post-sale holding value | ~$705,000 |
| Market cap | $3.28 billion |
| Revenue (TTM) | $415.62 million |
| 1-year price change | +89.65% |
| Q1 ZORYVE net product revenue | $105.4 million (+65% YoY) |
| Q1 net loss | $11.3 million (vs. $25.1M prior year) |
| Full-year revenue guidance | $480M–$495M |
Frequently Asked Questions
Why did Sue-Jean Lin sell Arcutis shares?
The sale was executed under a prearranged trading plan, which insiders set up in advance to sell shares on a fixed schedule. This type of plan is generally considered routine portfolio management rather than a response to company-specific concerns.
How much of her stake did Lin sell?
Lin sold roughly 15% of her direct holdings, reducing her position from approximately 32,513 shares to 27,567 shares. She retains a direct stake valued near $705,000 at the June 15 closing price.
What is ZORYVE and why does it matter to Arcutis?
ZORYVE is Arcutis' flagship franchise of topical dermatology treatments. It generated $105.4 million in net product revenue in Q1 2026, a 65% year-over-year gain, and is the primary driver of the company's commercial growth.
What is Arcutis' financial outlook for 2026?
The company is guiding for full-year 2026 revenue between $480 million and $495 million. It reported positive operating cash flow in Q1 and a narrowing quarterly net loss of $11.3 million.
What to Watch Next
Arcutis enters the back half of 2026 with ZORYVE still gaining prescription share and two pipeline catalysts on deck — the supplemental FDA filing for younger patients and early data from the ARQ-234 first-in-human study. How quickly those milestones materialize, and whether the company can push into consistent profitability, will define the stock's next chapter far more than one director's scheduled share sale.
